What did @jessicashepherdmd actually say?
She said a lot, quickly. The core argument: as estrogen and testosterone decline with age, muscle mass drops, fat cells change behavior, insulin resistance increases, cortisol rises, and abdominal fat accumulates. Her proposed fix is a package deal: HRT with both estrogen and testosterone, reduced processed foods, more fiber, creatine for muscle, and ashwagandha for cortisol. She name-dropped creatine as "Cretin" twice, which is a mispronunciation worth noting if you're searching for supplements.
She framed this as mechanistic cause-and-effect: declining hormones drive insulin resistance, which drives cortisol, which drives fat storage. That's a reasonable clinical narrative, but it's compressed to the point where several important nuances disappear entirely. She stopped short of making any specific dosing claims, which is good. She did imply HRT is a direct treatment for belly fat accumulation, which requires more careful qualification than she gave it.
Does the science back this up?
Partially, yes. The estrogen-insulin sensitivity link is real and reasonably well-supported. The testosterone-muscle mass connection is solid. The jump to cortisol as a direct downstream consequence of declining estrogen is where things get shakier.
Estrogen does appear to influence insulin sensitivity through multiple pathways. A 2020 review by Mauvais-Jarvis in Physiological Reviews documented that estradiol acts on pancreatic beta cells and peripheral tissues to improve glucose uptake, and that estrogen loss at menopause correlates with increased visceral adiposity and insulin resistance in both human and animal models. That part checks out.
On testosterone: skeletal muscle does express androgen receptors, and testosterone supports protein synthesis and lean mass. A 2019 meta-analysis by Isidori et al. in Journal of Clinical Endocrinology and Metabolism found testosterone therapy in women with low levels improved body composition, though effect sizes on visceral fat specifically were modest. She's not wrong, but the effect is smaller than her framing implies.
The cortisol claim is the weakest link. She described a chain where insulin resistance "drives cortisol up," which is an oversimplification. The relationship between cortisol and insulin resistance is bidirectional, not a clean one-way street. Chronic stress elevates cortisol, which can worsen insulin resistance, but framing cortisol as a downstream output of insulin resistance misrepresents the mechanism.
What did they get wrong (or right)?
She got the broad strokes right. Menopause-associated hormone decline does contribute to changes in body composition and metabolic function. That is supported science, not wellness speculation.
What she got wrong, or at least poorly explained:
- The cortisol mechanism is reversed in her telling. Cortisol dysregulation often precedes or worsens insulin resistance, not the other way around. A 2015 paper by Baudrand and Vaidya in Best Practice and Research: Clinical Endocrinology and Metabolism outlined how glucocorticoid excess directly impairs insulin signaling in adipose and muscle tissue.
- She implied HRT directly reduces abdominal fat. The evidence is more nuanced. A 2019 Cochrane review by Marjoribanks et al. found HRT can shift fat distribution away from visceral deposits, but it does not reliably produce net fat loss without accompanying lifestyle changes.
- Ashwagandha's cortisol effects are real but modest. A 2019 randomized controlled trial by Choudhary et al. in Medicine showed significant cortisol reduction versus placebo, but effect sizes are not dramatic enough to frame it as a major metabolic intervention without more context.
- Creatine for glucose metabolism is legitimate but undersold as a mechanism. A 2011 study by Gualano et al. in Medicine and Science in Sports and Exercise found creatine supplementation improved glycemic control in type 2 diabetes patients doing resistance training. It works, but primarily in the context of exercise, not as a standalone metabolic fix.
What should you actually know?
The belly fat and menopause connection is real. But no single intervention, including HRT, fixes it in isolation. The honest version of this conversation is that declining estrogen changes where and how your body stores fat, particularly shifting toward visceral accumulation. That has real metabolic consequences.
If you're perimenopausal or postmenopausal and concerned about metabolic changes, the evidence supports a combination approach: appropriate hormone therapy if you're a candidate, resistance training, dietary changes, and potentially adjunct supplements. That is roughly what she said. The problem is she packaged it as though each piece is equally well-evidenced, and they're not.
Ashwagandha and creatine have genuine supporting data, but neither should be positioned as cornerstones of a metabolic strategy. They're supporting players, not leads.
On HRT specifically: it is not FDA-approved as a weight management drug or a belly fat treatment. It can improve body composition as a secondary effect in women with hormone deficiency. If you're considering HRT, that conversation belongs with a clinician who can assess your full history, not an Instagram video, including this one.